Please login to the form below

Not currently logged in
Email:
Password:

CHMP recommends Erbitux

Merck Serono has announced that the Committee for Medicinal Products for Human Use has given a positive recommendation for an application to extend the uses of its cancer drug, Erbitux
Merck Serono has announced that the Committee for Medicinal Products for Human Use (CHMP) has given a positive recommendation for an application to extend the uses of its cancer drug, Erbitux.

The drug has already been approved for the treatment of colorectal cancer (CRC) in Europe and was licensed for use on the market in June 2004. Merck and Serono hope to extend the use of Erbitux to include the treatment of metastatic colorectal cancer (mCRC) with KRAS wild-type tumours, and is to be used in combination with chemotherapy.

The company, a division of global pharmaceutical manufacturer and developer, Merck, said that the scientific committee at the European Medicines Agency (EMEA) also gave its backing for the application.

Dr Wolfgang Wein, executive vice-president of oncology at Merck, said: "The positive opinion from the CHMP is an important step forward in the management of CRC and a step closer to tailored therapy for cancer patients."

30th May 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics